Information for the public

Midostaurin (Rydapt) is available on the NHS as a possible treatment for newly diagnosed (untreated) acute FLT3-positive myeloid leukaemia in adults. It is taken as:

  • induction therapy (with standard daunorubicin and cytarabine)
  • consolidation therapy (with high-dose cytarabine) and
  • alone as maintenance therapy if there has been a complete response to treatment.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about making decisions about your care.

Questions to think about

  • How well does it work compared with other treatments?
  • What are the risks or side effects? How likely are they?
  • How will the treatment affect my day-to-day life?
  • What happens if the treatment does not work?
  • What happens if I do not want to have treatment? Are there other treatments available?

Information and support

NHS Choices may be a good place to find out more.

These organisations can give you advice and support:

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2967-2


This page was last updated: